Company profile for Greenwich LifeSciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and is planning to commence a Phase III clinical trial. GP2 is derived from the HER2/neu protein, which is expressed in a variety of common cancers, including breast cancer. Tumors with elevated expression of HER2/neu protein are highly aggressive, resulting in a...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide immunotherapy, and is planning to commence a Phase III clinical trial. GP2 is derived from the HER2/neu protein, which is expressed in a variety of common cancers, including breast cancer. Tumors with elevated expression of HER2/neu protein are highly aggressive, resulting in an increased disease recurrence and a worse prognosis.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
3992 Bluebonnet Drive Building 14 Stafford, TX 77477
Telephone
Telephone
(832) 819-3232
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/10/09/3163955/0/en/Greenwich-LifeSciences-Announces-Addition-of-Austria-to-Flamingo-01-Clinical-Trial.html

GLOBENEWSWIRE
09 Oct 2025

https://www.globenewswire.com/news-release/2025/10/02/3160199/0/en/Greenwich-LifeSciences-Announces-Expansion-of-Flamingo-01-Clinical-Trial-to-Belgium.html

GLOBENEWSWIRE
02 Oct 2025

https://www.globenewswire.com/news-release/2025/09/30/3158379/0/en/Greenwich-LifeSciences-Announces-Addition-of-Portugal-to-Flamingo-01-Clinical-Trial.html

GLOBENEWSWIRE
30 Sep 2025

https://www.globenewswire.com/news-release/2025/09/18/3152237/0/en/Greenwich-LifeSciences-Announces-Expansion-of-Flamingo-01-Clinical-Trial-to-Ireland.html

GLOBENEWSWIRE
18 Sep 2025

https://www.globenewswire.com/news-release/2025/09/10/3147584/0/en/Greenwich-LifeSciences-GLSI-100-Granted-US-FDA-Fast-Track-Designation.html

GLOBENEWSWIRE
10 Sep 2025

https://www.globenewswire.com/news-release/2025/08/20/3136494/0/en/Noble-Capital-Markets-Initiates-Equity-Research-Coverage-on-Greenwich-LifeSciences.html

GLOBENEWSWIRE
20 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty